Source disclosure: January 29, 2026
Carna Biosciences,Inc. [4572.T]
TOKYO — Carna Biosciences, Inc., represented by President and CEO Koichiro Yoshino (stock code: 4572), announced on January 29 that its board has resolved to repurchase and cancel all outstanding shares of its First Tranche Convertible Bond with Warrant attached issued on July 11, 2025. The company also decided to issue new unsecured bonds and warrants through a private placement to Cantor Fitzgerald Europe.
The decision was made during a board meeting held on January 29, 2026, following a resolution passed on February 17, 2025. According to the announcement, Carna Biosciences will buy back all remaining shares of the First Tranche Convertible Bond with Warrant at face value, amounting to ¥250 million. This move is part of a broader capital restructuring strategy aimed at stabilizing the company's financial foundation.
Additionally, the company plans to raise approximately ¥4.746 billion through this financing arrangement, which includes issuing ¥1.711 billion worth of unsecured ordinary bonds and expecting ¥3.015 billion from the exercise of newly issued warrants. A portion of these funds, specifically ¥1.850 billion from warrant exercises, will be used to repay the aforementioned bonds. The total net proceeds after accounting for issuance costs and other adjustments are estimated at ¥2.896 billion.
Furthermore, the company intends to issue new shares to Mr. Yoshino, the company’s representative director, as part of the same financing plan. However, due to his conflict of interest, Mr. Yoshino did not participate in the board resolution concerning the share issuance. The funds raised will primarily support clinical development expenses for docirbrutinib (AS-1763) and monzosertib (AS-0141), research and manufacturing costs for developmental compounds, operational funding, and repayment of existing debt obligations.
Specifically, the allocation of funds is detailed as follows: ¥1.335 billion for clinical development costs of AS-1763 and AS-0141 between February 2026 and April 2027; ¥762 million for non-clinical research and manufacturing costs up until April 2027; ¥529 million for operating capital needs over the same period; and ¥2.100 billion for bond repayments and the cancellation of the first tranche convertible bond with warrant. These allocations aim to ensure steady progress in the company's drug development pipeline while maintaining financial stability.
AI-translated content. 🟢 Confidence: High See terms • Original filing